Bioregulators & Organ Support
Thymalin
← Back to LibraryEducational research reference. This page was restored from the structured compound dataset included with this site export. Protocol examples are context for review and are not medical advice.
At a glance
Route(s)
Subcutaneous
Target
Thymus
Timing window
Anytime
Regulatory status
no approved label identified
Protocol context
Standard Protocol
| Timeframe | Dose / exposure | Notes |
|---|---|---|
| Days 1-10 | 10mg daily | Standard Russian clinical protocol. 10 consecutive days. Can be administered at any time of day. Repeat every 6 months. |
Alternative Titration 1: Quarterly Low-Dose Maintenance Protocol (Goal: sustained year-round thymopoietic support with reduced per-cycle intensity; preferred for subjects with well-maintained immune function seeking longevity maintenance rather than active immunosenescence reversal)
| Timeframe | Dose / exposure | Notes |
|---|---|---|
| Days 1-10 (Q1) | 5mg 1x daily | Half-dose intensive course. Baseline lymphocyte subset panel (CD3/CD4/CD8/NK/naive T-cell) before first quarterly cycle. |
| Days 1-10 (Q2) | 5mg 1x daily | Repeat quarterly. No washout panel required between quarterly cycles in healthy subjects. |
| Days 1-10 (Q3) | 5mg 1x daily | Continue quarterly. |
| Days 1-10 (Q4) | 5mg 1x daily | Annual lymphocyte subset panel at Q4 completion to assess cumulative thymopoietic response. |
Alternative Titration 2: Intensive Immunosenescence Reversal Protocol (Goal: maximum thymic restoration for subjects with confirmed profound immunosenescence, low CD4+ count, severely reduced naive T-cell output, or recurrent infections; accelerated initial loading)
| Timeframe | Dose / exposure | Notes |
|---|---|---|
| Days 1-10 (Course 1) | 10mg 1x daily | First intensive course. Baseline lymphocyte subset panel (CD3, CD4, CD8, CD45RA naive T-cells, NK cells) required. If CD4+ < 300 or naive T-cell fraction < 10%, this double-course protocol is indicated. |
| Days 21-30 (Course 2) | 10mg 1x daily | 10-day washout between courses, then second full-dose course. Double-course loading for severe immunosenescence. Lymphocyte panel recheck before Course 2 initiation. |
| Days 91-100 (Course 3) | 10mg 1x daily | 3-month interval maintenance course. After the initial double loading, return to standard biannual schedule if immune markers trending toward normal. |
Alternative Titration 3: Pre-Vaccination Immune Priming Protocol (Goal: maximize vaccine immunogenicity by restoring naive T-cell output and T-cell receptor repertoire breadth before novel antigen exposure; initiate 4 weeks before scheduled vaccination)
| Timeframe | Dose / exposure | Notes |
|---|---|---|
| Days 1-10 (4 weeks before vaccination) | 10mg 1x daily | Full standard course beginning 4 weeks before scheduled vaccination date. Goal is to maximize circulating naive T-cell numbers and TCR repertoire diversity before antigen challenge. Most relevant for elderly subjects (65+) or immunosenescent subjects where influenza, pneumococcal, herpes zoster, or COVID-19 vaccine seroconversion rates are suboptimal. |
| Days 1-5 (1 week post-vaccination) | 5mg 1x daily | Post-vaccination consolidation half-dose course. Supports the expanding antigen-specific T-cell clonal response during the 7-14 day consolidation window following vaccination. Strengthens the T-cell memory formation phase. |
Alternative Titration 4: Post-Chemotherapy Immune Reconstruction Protocol (Goal: systematic thymic restoration following chemotherapy-induced lymphopenia and bone marrow suppression; minimum 4 weeks post-chemotherapy with ANC recovery confirmed before initiating)
| Timeframe | Dose / exposure | Notes |
|---|---|---|
| Weeks 1-2 | 1mg 1x daily | Ultra-conservative entry. ANC must be > 1.0 × 10⁹/L before initiating. Platelet count > 75 × 10⁹/L. Requires oncology/hematology supervision. The involuted thymus emerging from chemotherapy-mediated lymphodepletion requires gradual re-stimulation to avoid excessive immune activation before marrow recovery is consolidated. |
| Weeks 3-4 | 2mg 1x daily | Dose escalation. CBC weekly monitoring. Continue if ANC trending upward. |
| Weeks 5-8 | 5mg 1x daily | Mid-dose phase. Lymphocyte subset panel at week 6 to document T-cell recovery progress. |
| Weeks 9-12 | 10mg 1x daily | Full standard dose. Initiate only when ANC > 1.5 × 10⁹/L and CD4+ trending toward 200+. Combine with Thymosin Alpha-1 from week 9 for simultaneous T-cell activation support alongside thymic output restoration. |
Alternative Titration 5: Khavinson Longevity Stack: Thymalin + Epithalon + Crystagen Sequential Protocol (Goal: replicate the multi-axis thymic/telomeric/peripheral-immune intervention structure that produced the Khavinson mortality outcome data; thymic restoration followed by telomere protection followed by peripheral immune normalization)
| Timeframe | Dose / exposure | Notes |
|---|---|---|
| Days 1-10 | 10mg Thymalin 1x daily + 5mg Epithalon SC at bedtime | Concurrent Thymalin and Epithalon. Thymalin at any time of day; Epithalon at bedtime. This precisely mirrors the core structure of the Khavinson longevity studies that demonstrated 28-45% all-cause mortality reduction. Baseline immune panel, telomere length, and biological age assessment before initiating. |
| Days 11-20 | 5mg Epithalon SC at bedtime (Thymalin course complete) | Thymalin standard 10-day course is complete. Continue Epithalon for its full 20-day course. The newly thymopoietically restored immune system during Days 11-20 coincides with continued TERT activation: the biological window where the newly exported naive T-cells encounter Epithalon's circadian/telomeric normalization. |
| Days 21-30 | Crystagen 500mcg-2mg SC 1x daily (begin Crystagen standard course) | Sequential peripheral immune normalization with Crystagen immediately following Epithalon completion. Crystagen normalizes peripheral T-cell and NK cell functional programs in the newly expanded naive T-cell population that Thymalin produced. The sequential structure: thymic output (Thymalin) → telomere protection (Epithalon) → peripheral immune normalization (Crystagen): provides comprehensive immune aging intervention across all three levels. |
Protocol logic
Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Thymus); route Subcutaneous; timing Anytime. Unapproved or source-dataset dosing tables are hypotheses, not recommendations.
Side effects / cautions listed in dataset
- Injection site redness and mild erythema: the most commonly reported adverse effect; rare given Thymalin's exceptional tolerability profile; self-resolving.
- Mild transient fatigue: occasionally reported in the first 2-3 days of the 10-day course; related to thymic activation and immune response initiation.
- Low-grade fever: uncommon; associated with the initial immune activation cascade; typically resolves within 48 hours.
- Mild flu-like symptoms: rare; consistent with early immune activation; self-limiting.
- Temporary lymphocyte redistribution: a pharmacodynamic effect rather than an adverse event; circulating lymphocytes may transiently decrease before the new naive T-cell output increases peripheral counts; not clinically significant in immunocompetent subjects.
- Theoretical autoimmune exacerbation: in subjects with subclinical autoimmune predisposition; the immune competence restoration from Thymalin could unmask previously suppressed autoimmune activity.
- No documented endocrine disruption, HPA axis effects, or hormonal side effects: Thymalin's activity is confined to the thymic/immune system axis.
- No documented tachyphylaxis: the twice-yearly protocol maintains efficacy across multiple years of administration without diminishing returns in the published Russian clinical literature.
Contraindications / risk flags listed in dataset
- Organ transplant recipients: Thymalin's thymic restoration and T-cell education activity directly counteracts the immunosuppressive regimens required to prevent allograft rejection; thymic peptide delivery in the context of transplant immunosuppression creates acute rejection risk; absolute contraindication.
- Active autoimmune disorders with significant T-cell-mediated pathology (rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Type 1 diabetes): Thymalin increases naive T-cell output and T-cell activation; in conditions where pathological T-cells are already attacking self-tissue, restoring immune competence without correcting the autoimmune drive may amplify tissue destruction.
- Active graft-versus-host disease: T-cell expansion and activation in the context of GVHD is dangerous.
- Concurrent immunosuppressive therapy (calcineurin inhibitors, high-dose corticosteroids, mycophenolate): the fundamental pharmacological opposition between Thymalin's immunorestorative activity and immunosuppressive drugs makes combined use counterproductive and potentially destabilizing.
- Active hematological malignancy involving T-cell lineages (T-cell lymphoma, T-cell leukemia): Thymalin's T-cell education and expansion activity could stimulate malignant T-cell proliferation.
- Known hypersensitivity to Thymalin, bovine thymic extracts, or excipients.
- Pregnancy: thymic peptide immunomodulation during fetal immune system development is not established as safe.
- Breastfeeding: no safety data.